Tango Therapeutics TNGX Revaluation Of Right Of Use Asset And Lease Liability Upon Lease Modification
Revaluation Of Right Of Use Asset And Lease Liability Upon Lease Modification at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept tngx:RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification.
The official record: Tango Therapeutics’s 10-Q, filed August 5, 2025, on SEC EDGAR. View the filing →
Ask your AI about Tango Therapeutics's revaluation of right of use asset and lease liability upon lease modification.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tango Therapeutics's revaluation of right of use asset and lease liability upon lease modification?
- Tango Therapeutics (TNGX) reported revaluation of right of use asset and lease liability upon lease modification of $1.12M in Q2 2025.
- What is the long-term trend for Tango Therapeutics's revaluation of right of use asset and lease liability upon lease modification?
- Over 2 years (2021 to 2023), Tango Therapeutics's revaluation of right of use asset and lease liability upon lease modification has grown at a -79.3% compound annual growth rate (CAGR), from $5.32M to -$228K.
- What does revaluation of right of use asset and lease liability upon lease modification mean?
- Reflects adjustments to the carrying value of right-of-use assets and lease liabilities due to modifications in lease terms. This non-cash metric captures changes in the expected duration or cost of existing lease contracts. It provides insight into the management of long-term operational commitments and asset utilization.